Bionovate looks to capitalise upon the dramatic increase in scientific research into the applications of biologically-active anti-inflammatory lipids from naturally derived compounds which can be commercially licensed for development by major consumer healthcare oriented marketing partners.
Some of Bionovate’s ingredients that are used in products such as Regenovex, a range of oral and topical applications for problem joints. The products are developed in collaboration with UK universities and processing takes place at their newly refurbished units in New Zealand.
Keith Bowhill, director of Bionovate, said: “At Bionovate we are bucking the trend by demonstrating rapid growth and development. As well as securing a number of high profile contracts with blue chip companies we are conducting a number of research projects to develop our product range further.
“Our products are manufactured to the highest level of quality and this has been recognised by a number of blue chip organisations who employ our services. The new funding provided by NatWest gives us a sound platform from which to expand and explore new opportunities.”
Bionovate has a pipeline of products in various disease categories in development over the next few years. The company’s current focus of R&D is on: Novel lipid extraction technology; Innovative glycosaminoglycan extraction; and combination patents for major disease categories, such as arthritis, asthma and diabetes
Bionovate is focussed on Bioscience projects, specializing in the extraction of potent anti-inflammatory fatty acids such as Bionovex, derived from marine-sources. Bionovate claims that it has the potential to develop future products targeted for dermatitis, asthma and oral health and which will utilise its nanomolecular filtration technology that allows the anti-inflammatory fatty acid extracts to be produced with far greater concentration.
Tony Chandler, co-director of Bionovate, said: “The funds from the EFG scheme will help improve our production capacity for Bionovex and the existing range of products like Regenovex and ensures we have the control over the entire production-supply chain from mussels growing in New Zealand straight through to our distributors.
“We plan to further develop nanomolecular filtration technology, which is an innovative and novel means of extracting the potent anti-inflammatory fatty acids found naturally in our marine-derived extracts, and use this for our future product developments.”